Incretin Launch Monitor: Latest Rx Trends For Key Diabetes/Obesity Drugs

研报英文原文证据摘录

Incretin Launch Monitor: Latest Rx Trends For Key Diabetes/Obesity Drugs

ial Promotion Order"), (ii) are persons falling

within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations, etc.") of the Financial Promotion Order, or (iii) are persons to whom an invitation

or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or

sale of any securities may otherwise lawfully be communicated or caused to be communicated. Insofar as the document is issued in or to the European Union, it is

intended only to be issued to persons categorized as 'Per Se Professional' or 'Eligible Counterparties' as defined in S.I. No 375 of 2017, European Union (Markets in

Financial Instruments) Regulations 2017, Schedule 2. Clients in the United Kingdom wishing to effect transactions in any security discussed herein should do so through

a qualified salesperson of TD Bank Europe Limited. European clients wishing to effect transactions in any security discussed herein should do so through a qualified

salesperson of TD Global Finance unlimited company. Article 20 Market Abuse Regulation 596/2014 ("MAR") requires market participants who produce or disseminate

Investment Recommendations or other information recommending or suggesting an investment strategy to take reasonable care that such information is objectively

presented, and to disclose their interests or indicate conflicts of interest.

In accordance with the MAR requirements, see the Investment Recommendations Disclaimer for relevant information in relation to The Toronto-Dominion Bank –

London Branch, TDBEL and TD Global Finance unlimited company. https://www.tdsecurities.com/tds/document/MAR-IR-Disclaimer.